Inactive Instrument

Pediatrx Inc Share Price OTC Bulletin Board

US70532X1072

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

18/02/25	Ignite Proteomics LLC acquired Proprietary Laboratory Analyses code 0249U from Theralink Technologies, Inc..	CI
06/05/24	IMAC Holdings, Inc. acquired Assets of Theralink Technologies, Inc.	CI

Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	615K 531K 499K 454K 853K 58.8M 866K 5.85M 2.29M 29.46M 2.31M 2.26M 98.04M	P/E 2022	-1.59x	P/E 2023	-0.18x
Enterprise Value	19.38M 16.73M 15.71M 14.3M 26.88M 1.85B 27.27M 184M 72.12M 928M 72.75M 71.17M 3.09B	EV / Sales 2022	44,915,754x	EV / Sales 2023	40,045,900x
Free-Float	17.39%	Yield 2022 *	-	Yield 2023	-

18/02/25	Ignite Proteomics LLC acquired Proprietary Laboratory Analyses code 0249U from Theralink Technologies, Inc..	CI
06/05/24	IMAC Holdings, Inc. acquired Assets of Theralink Technologies, Inc.	CI
05/05/24	Theralink Technologies, Inc. cancelled the acquisition of IMAC Holdings, Inc. in a reverse merger transaction.	CI
20/02/24	Theralink Technologies, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI
05/01/24	Theralink Technologies, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	CI
04/01/24	Theralink Technologies, Inc. Auditor Raises 'Going Concern' Doubt	CI
03/11/23	Theralink Technologies, Inc. Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute?s Molecular Tumor Board	CI
21/08/23	Theralink Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	CI
25/07/23	IMAC Holdings, Inc. announced that it has received $4.3 million in funding from Theralink Technologies, Inc. and other investors	CI
27/06/23	Theralink Technologies, Inc. Announces Chief Executive Officer Changes	CI
27/06/23	Theralink Technologies, Inc. Appoints Mick Ruxin as Chief Medical Officer	CI
15/05/23	Theralink Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	CI
14/05/23	Theralink Technologies, Inc. entered into a definitive agreement and plan of merger to acquire IMAC Holdings, Inc. for $0.9 million in a reverse merger transaction.	CI

06/03/24	Theralink Technologies : Accelaration/Increase of Financial Obligation - Form 8-K	PU
18/12/23	Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates	AQ
13/11/23	Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4	AQ
03/11/23	Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board	AQ
05/10/23	Four Penny Stocks That Might Move On News (EPAZ, THER, SDNR, HNRC)	AQ

Manager	Title	Age	Since
Justin Davis CTO	Chief Tech/Sci/R&D Officer	-	30/11/2022
Michael Ruxin CEO	Chief Executive Officer	80	31/12/2017
Trevor McCartney SAM	Sales & Marketing	-	28/02/2019

Director	Title	Age	Since
Jeffrey Busch CHM	Chairman	68	17/06/2020
Michael Ruxin BRD	Director/Board Member	80	17/06/2020
Yvonne Fors BRD	Director/Board Member	54	17/06/2020

Pediatrx Inc Share Price OTC Bulletin Board

Stocks

US70532X1072

Biotechnology & Medical Research

Valuation: Pediatrx Inc

Latest news : Pediatrx Inc

Press Releases: Pediatrx Inc

Managers and Directors: Pediatrx Inc

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+4.80%	+7.80%	+70.64%	+114.21%	70.07B
ARGENX SE	+17.12%	+12.05%	+54.42%	+86.20%	52.87B
INSMED INCORPORATED	+3.70%	-2.12%	+0.41%	+469.55%	27.02B
WUXI BIOLOGICS (CAYMAN) INC.	+2.26%	+0.65%	+49.19%	+10.30%	23.61B
BIONTECH SE	-1.60%	-2.21%	-19.31%	-15.15%	23.38B
PHARMAESSENTIA CORPORATION	-6.00%	+13.71%	+244.39%	+443.26%	19.43B
GENMAB A/S	+3.80%	+5.25%	+40.50%	-16.41%	18.75B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.38%	-3.15%	+20.39%	+589.77%	15.85B
EXELIXIS, INC.	+2.11%	-3.24%	+36.57%	+145.40%	12.7B
Average	+2.95%	-2.08%	+55.25%	+203.01%	29.3B
Weighted average by Cap.	+5.10%	-1.14%	+56.29%	+169.29%

	2022	2023
Net sales	0.57 0.49 0.46 0.42 0.79 54.29 0.8 5.4 2.11 27.2 2.13 2.09 90.51	0.61 0.52 0.49 0.45 0.84 58 0.85 5.77 2.26 29.06 2.28 2.23 96.71
Net income	-12.74M -11M -10.33M -9.41M -17.67M -1.22B -17.93M -121M -47.42M -610M -47.84M -46.79M -2.03B	-30.91M -26.69M -25.06M -22.82M -42.87M -2.95B -43.49M -294M -115M -1.48B -116M -114M -4.93B
Net Debt	3.98M 3.43M 3.23M 2.94M 5.52M 380M 5.6M 37.83M 14.8M 190M 14.93M 14.61M 634M	18.76M 16.2M 15.21M 13.85M 26.03M 1.79B 26.4M 178M 69.83M 899M 70.44M 68.91M 2.99B